Related Experiment Video
Updated: Mar 27, 2026

11:29
Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain
Published on: October 3, 2012
11.3K
Single octapeptide deletion selectively processes a pathogenic prion protein mutant on the cell surface
Yumi Lee1, Duri Lee1, Ilho Choi1
1Department of Biomedical Sciences, University of Ulsan College of Medicine & Asan Institute of Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
Biochemical and Biophysical Research Communications
|January 18, 2016
Summary
A single octapeptide repeat deletion in prion protein (PrP) does not alter PrP levels alone. However, this mutation affects the cell surface processing and distribution of specific PrP mutants.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Prion diseases are linked to aberrant prion protein (PrP) metabolism.
- The role of octapeptide repeats in PrP metabolism is not fully understood.
Purpose of the Study:
- To investigate the impact of octapeptide repeat mutations on PrP metabolism.
- To explore how these mutations affect PrP processing and cellular localization.
Main Methods:
- Deletion mutation of a single octapeptide repeat in the PRNP gene in HeLa cells.
- Analysis of PrP levels, synthesis, distribution, and processing.
Main Results:
- A single octapeptide repeat deletion mutation alone did not affect overall PrP levels.
- This deletion selectively reduced PrP levels in the presence of other pathogenic mutations.
- The A117V PrP mutant showed altered cell surface distribution and processing with the octapeptide deletion.
Conclusions:
- Octapeptide repeat number influences PrP metabolism in a mutation-dependent manner.
- The study reveals novel insights into mutant-specific PrP metabolism on the cell surface.
Related Concept Videos
The Proteasome
10.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.5K
The Proteasome
2.0K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
2.0K
Export of Misfolded Proteins out of the ER
5.5K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
5.5K
Amyloid Fibrils
12.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.9K

